Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if TACE plus Sorafenib will improve outcome in
patients with advanced hepatocellular carcinoma (HCC) not amenable to surgery.